Back to Global Pulse
Systematic Review Examines Yerba Mate's Potential Role in Rheumatoid Arthritis Management
Health & Science February 28, 2026

Systematic Review Examines Yerba Mate's Potential Role in Rheumatoid Arthritis Management

A 2025 systematic review published in MDPI Nutrients concludes that Ilex paraguariensis constituents show preliminary anti-inflammatory and antioxidant effects relevant to rheumatoid arthritis, underscoring the need for dedicated clinical investigation.

Source: MDPI Nutrients / ResearchGate

AI Summary

Systematic review published MDPI 2025 examines yerba mate constituents for rheumatoid arthritis showing preliminary anti-inflammatory antioxidant effects relevant to autoimmune pathophysiology calling for clinical trials


A systematic review published in the MDPI-indexed journal Nutrients, with literature searches conducted through September 2025, has compiled and evaluated the existing evidence on yerba mate's potential relevance to rheumatoid arthritis (RA) — a chronic autoimmune condition affecting approximately 1% of the global population. The review, which synthesized data from preclinical studies, in vitro investigations, and limited human observational data, concludes that Ilex paraguariensis and its bioactive constituents demonstrate 'preliminary indications of anti-inflammatory and antioxidant effects relevant to RA pathophysiology.'

Mechanisms of Interest

Rheumatoid arthritis is driven by dysregulated immune activation, in which pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and reactive oxygen species (ROS) cause progressive joint destruction. The review identifies several yerba mate constituents with demonstrated activity against these pathways: chlorogenic acid (a potent scavenger of hydroxyl and superoxide radicals), rutin (which inhibits NF-κB-mediated cytokine production), and matesaponins (which modulate inflammatory signaling cascades including the COX-2 and iNOS pathways).

Evidence Assessment

The reviewers note that interventions with yerba mate infusions or extracts in the evaluated studies suggested reductions in inflammatory markers and improvements in oxidative balance. However, the evidence base remains predominantly preclinical, and the authors explicitly caution against drawing therapeutic conclusions from animal and cell-culture models alone. The heterogeneity of dosing protocols, extract preparations, and outcome measures across studies further limits the strength of pooled inferences.

What distinguishes this review is its methodological rigor in applying systematic search criteria to a body of literature that has largely been assessed only in narrative reviews. By establishing a structured evidence map, the authors provide a clear framework for the design of future clinical trials examining whether yerba mate consumption could serve as a complementary intervention for RA patients. The review recommends standardized extract protocols and validated RA-specific outcome measures (DAS28 scores, rheumatoid factor titers) as essential design elements for any prospective human study.